<DOC>
	<DOCNO>NCT03013439</DOCNO>
	<brief_summary>The trial open-label , 4 cohort , sequential , dose-escalating , single dose trial .</brief_summary>
	<brief_title>Dose-escalation Trial Safety , Pharmacokinetics , Pharmacodynamics Iron Isomaltoside ( Monofer® )</brief_title>
	<detailed_description>IDA highly prevalent subject cancer gastrointestinal disease inflammatory bowel disease , menstruate pregnant woman , subject undergone bariatric procedure . IDA substantial medical quality life ( QoL ) burden subject , treatment subject include control bleed replenish lose iron .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Iron Metabolism Disorders</mesh_term>
	<mesh_term>Iron</mesh_term>
	<criteria>1 . Japanese man woman ≥ 20 year , &lt; 65 year age 2 . Hb ≥ 9.0 g/dL , &lt; 12.0 g/dL woman &lt; 13.0 g/dL men 3 . Serum ferritin &lt; 25 ng/mL 4 . TIBC ≥ 360 μg/dL 5 . Body weight ≥ 50 kg 6 . Willingness participate signing informed consent form Exclusion criterion include : 1 . Anemia cause condition iron deficiency 2 . Cancer 3 . IV oral iron treatment , blood transfusion 4 week prior screen 4 . Erythropoiesis stimulate agent ( ESA ) treatment prior screen 5 . Imminent expectation blood transfusion part treat physician 6 . Iron overload disturbance ( e.g . hemochromatosis hemosiderosis ) 7 . Known hypersensitivity reaction iv iron preparation 8 . Decompensated liver cirrhosis active hepatitis 9 . Active acute chronic infection 10 . Pregnant nursing woman . 11 . Planned elective surgery trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>